Types of Endocrine Disorders: Which Are Being Studied With Stem Cell Therapy?

"Endocrine disorder" covers an unusually wide range of conditions, from type 1 diabetes to thyroid disease, adrenal insufficiency, and polycystic ovary syndrome (PCOS) — each involving a different gland, different hormones, and a different reason stem cell researchers find it interesting. This article walks through where the science actually stands for several major endocrine conditions, so readers can tell the difference between an approach already in late-stage human trials and one that is still confined to mice.

What Makes Endocrine Disorders Different

Most endocrine disorders fall into one of two buckets that matter a great deal for regenerative medicine. Some, like type 1 diabetes and autoimmune thyroid disease, are caused by the immune system attacking and destroying hormone-producing cells — which makes them targets for both cell replacement (growing new hormone-producing cells) and immune modulation (calming the attack). Others, like PCOS, are not primarily autoimmune but involve dysfunction within the gland's own supporting tissue, inflammation, and signaling problems — which has pushed researchers toward mesenchymal stem cell (MSC) secretions rather than cell replacement. That split explains why the research below looks so different from one condition to the next.

Type 1 Diabetes: The Endocrine Disorder Furthest Along

Of every endocrine condition, type 1 diabetes has the most advanced stem cell science. Vertex Pharmaceuticals' stem cell-derived islet cell therapy, now called zimislecel (formerly VX-880), is manufactured from stem cells and implanted to replace the insulin-producing beta cells that autoimmune disease destroys. Vertex reported positive, durable clinical data from its ongoing trial program through 2025 and continues advancing the therapy toward a regulatory filing. This is a genuinely promising, clinically advanced program — but it still requires immunosuppression in most current protocols, and it is not yet an approved therapy. Readers wanting the full picture on diabetes-related regenerative research — including diabetic complications like neuropathy and retinopathy — should see our dedicated "Types of Diabetes and Diabetic Complications" article, since this piece focuses on other endocrine glands.

Autoimmune Thyroid Disease: Hashimoto's and Graves'

Hashimoto's thyroiditis and Graves' disease are the two most common autoimmune thyroid conditions, and stem cell research here is markedly earlier-stage than in diabetes. A 2017 study in Experimental and Therapeutic Medicine found that mesenchymal stem cells engineered to express ICAM-1 reduced thyroid damage and normalized hormone and autoantibody levels in mice with experimental autoimmune thyroiditis, apparently by improving how well the cells homed to the thyroid and dampened inflammatory signaling. That is a meaningful preclinical signal, but it comes from an animal model, not a human trial, and no engineered-MSC therapy for thyroid autoimmunity has reached clinical testing in people as of this writing.

Addison's Disease (Primary Adrenal Insufficiency)

Addison's disease, in which autoimmune destruction leaves the adrenal glands unable to produce enough cortisol, has drawn a different kind of regenerative interest: can the gland's own residual stem/progenitor cells be coaxed back into action, or can lab-grown adrenal tissue eventually replace it? A UK proof-of-principle study (RoSA) tested whether extended ACTH stimulation could revive dormant adrenocortical stem cell activity in people with established Addison's disease. Separately, researchers including Kotaro Sasaki's lab have built pluripotent stem cell-derived adrenocortical organoids that produce cortisol and androgens in response to ACTH in preclinical models, with transplantation into patients described as a future goal rather than a current reality. Both lines of work are early and have not produced an approved or widely available treatment.

Polycystic Ovary Syndrome (PCOS)

PCOS research has concentrated on MSC-derived extracellular vesicles (EVs), the tiny signaling packages MSCs release, rather than the cells themselves. In mouse models, MSC-derived EVs lowered androgen-producing gene activity, improved metabolic markers like blood glucose, and restored ovarian function, with researchers suspecting the anti-inflammatory protein IL-10 plays a role. This remains animal-model evidence. Human testing is only beginning: a registered, actively recruiting early-phase trial (ClinicalTrials.gov NCT06143527) is evaluating the safety of umbilical cord- or placenta-derived MSCs in women with PCOS — a safety-focused first step, not evidence of benefit.

How to Evaluate Claims in This Space

Because endocrine stem cell research spans everything from an FDA-track cell therapy to single mouse studies, the gap between "studied" and "proven" is especially wide here. Before weighing any claim, check whether the evidence involves human participants or only animal models, whether it comes from a registered trial (searchable on ClinicalTrials.gov) or a lab-only preprint, and whether a clinic is offering an unproven procedure based on early-stage science from a completely different condition. A legitimate adrenal or thyroid stem cell trial should be traceable to a specific registered study, not a general claim about "regenerative medicine" for hormone problems.

Bottom Line

Stem cell science is reshaping how researchers think about endocrine disease, but unevenly. Type 1 diabetes has an advanced, trial-stage cell replacement therapy; autoimmune thyroid disease, Addison's disease, and PCOS each have real, published research programs, but all remain in preclinical or early human safety testing. None of these earlier-stage conditions currently has an approved stem cell treatment, and patients should treat any clinic offering one as a claim to verify, not a fact to accept.